Home › Companies › ARTV

Artiva Biotherapeutics

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. AlloNK RA Ph3 start2H 2026AlloNK RA Ph3 start, 2H 2026, notable
  2. AlloNK + rituximab ACR interimNov 9, 2026AlloNK + rituximab ACR interim, Nov 9, 2026, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (14 active programs)

AlloNK

AB-101
Cell Target: CD20, CD19, CD16

AB-202

  • Undisclosed indication GC Cell

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.